scholarly journals How Much Market Access? A Case Study of Jordan's Exports to the EU

2018 ◽  
Vol 18 (3) ◽  
pp. 431-449 ◽  
Author(s):  
STEPHANIE BRUNELIN ◽  
JAIME DE MELO ◽  
ALBERTO PORTUGAL-PEREZ

AbstractThe value of preferential market access schemes has fallen sharply. Drawing on a relaxation announcement of July 2016 simplifying origin requirements for access to the EU that should help improve market access, thereby contributing to alleviate the refugee crisis in Jordan, this paper argues that a simplification of origin requirements is a straightforward way to enhance preferential market access. Yet, the EU decision limits the beneficiaries who must be located in designated special economic zones, which limits preferential market access. The paper compares the performance of Jordanian exports to the EU and the US under their respective FTAs. It shows that Jordanian exports to the US have grown more rapidly than exports to the EU over the last 15 years. The study documents lower utilisation of preferences in the EU than in the US, especially in Textiles and Apparel (T&A) in spite of non-negligible preferences. Three contributing factors are identified: (i) higher adjusted preferences for apparel in the US than in the EU; (ii) greater competition from other suppliers (mostly from LDCs) in the EU market than in the US market; (iii) simpler origin requirements in the case of the Jordan–US FTA. Comparative evidence from the two FTAs and econometric estimates suggest that this should help restore market access for Jordanian exports to the EU. These estimates provide additional evidence that origin requirements suppress market access. Other pathways to simplify origin requirements are offered in the conclusion.

Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 48
Author(s):  
Ioana Gherghescu ◽  
M. Begoña Delgado-Charro

Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior to the regulatory approval. European Medicines Agency (EMEA, currently EMA) and Food and Drug Administration (FDA) repositories were searched to identify all biosimilar medicines approved before December 2019. Adalimumab biosimilars, and particularly their clinical evaluations, were used as a case study. In the past 13 years, the EMA has received 65 marketing authorization applications for biosimilar medicines with 55 approved biosimilars available in the EU market. Since the first biosimilar approval in 2015, the FDA has granted 26 approvals for biosimilars with only 11 being currently on the US market. Five adalimumab biosimilars have been approved in the EU and commercialized as eight different medicines through duplicate marketing authorizations. Whilst three of these are FDA-approved, the first adalimumab biosimilar will not be marketed in the US until 2023 due to Humira’s exclusivity period. The EU biosimilar market has developed faster than its US counterpart, as the latter is probably challenged by a series of patents and exclusivity periods protecting the bio-originator medicines, an issue addressed by the US’s latest ‘Biosimilar Action Plan’.


2019 ◽  
Vol 37 (4) ◽  
pp. 465-481
Author(s):  
Evan Healey ◽  
Hareem Hilal ◽  
Kathrine Cornali Lerche ◽  
Shao Yan Ng ◽  
Grace Osberg ◽  
...  

Author(s):  
Jean-Christophe Bureau ◽  
Luca Salvatici

Abstract This paper provides a summary measure of the possible new commitments in the area of agricultural market access undertaken by the European Union and the United States, using the Trade Restrictiveness Index (TRI) as the tariff aggregator. We take the 2001 bound tariffs as the starting point and attempt to assess how much liberalization in agriculture could be achieved in the European Union and the United States as a result of the present negotiations. We compute the index for 20 agricultural commodity aggregates under the actual commitments assuming a specific functional form for import demand. We compare the present levels of the TRI with three hypothetical cases: a repetition of the same set of tariff cuts commitments of the Uruguay Round according to a EU proposal prior to the 2003 WTO ministerial meeting, a uniform 36% reduction of each tariff, an harmonization ( "Swiss" ) formula based on the initial US proposal.


2020 ◽  
Vol 4 (1) ◽  
pp. 77-90
Author(s):  
Hilmar Þór Hilmarsson

Ukraine’s history has been a turbulent one, and currently the country is in a crisis. The purpose of the article is to discuss how Ukraine can move away from the current East-West competition that poses a risk of dividing the country into two. What does it take to move a united Ukraine forward? How can Ukraine progress economically, politically and improve its security profile? The methodology used in the article is the case study method and it often compares Ukraine’s performance with Poland, a country of a similar size in terms of population, land mass, and located in geographic proximity. The article argues that more inclusive and sustainable growth in Ukraine will require increased productivity of the economy, more benefits from international trade and investment supported by closer integration into the global economy, as well as a well-governed domestic economy with stronger institutions to withstand pressures from vested interests. The US, EU and NATO must make more efforts to help Ukraine resolve the current conflict with Russia, which in turn needs to stop the military engagement in Ukraine to let it recover and benefit from integration and cooperation with the West. NATO membership and full EU membership should not be considered for now, but Ukraine should be an independent and neutral buffer state between the East and the West, with full access to the EU common market. Ukraine needs increased financial support, especially from the EU, US, IMF and the World Bank for its reconstruction.


Sign in / Sign up

Export Citation Format

Share Document